Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells

Journal of Cellular Physiology

Volumn 226, Issue 9, 2011, Pages 2279-2286

  Corallini, Federica ^a   Celeghini, Claudio ^b   Rimondi, Erika ^a   di Iasio, Maria Grazia ^a   Gonelli, Arianna ^a   Secchiero, Paola ^a   Zauli, Giorgio ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYTOKINE RECEPTOR; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; STROMAL CELL DERIVED FACTOR 1;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL TYPE; COCULTURE; CYTOTOXICITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LYMPHOMA CELL; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; STROMA CELL; SUPERNATANT;

BONE MARROW CELLS; CELL DEATH; CELLS, CULTURED; COCULTURE TECHNIQUES; DOWN-REGULATION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MESENCHYMAL STEM CELLS; OSTEOPROTEGERIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; RECOMBINANT PROTEINS; STROMAL CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958719390     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22564     Document Type: Article

References (43)

1. Albini A, Tosetti F, Benelli R, Noonan DM. 2005. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 65: 10637-10641.
2. Audo R, Combe B, Coulet B, Morel J, Hahne M. 2009. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases. Cell Death Differ 16: 1227-1237.
3. Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I. 2006. Osteoprotegerin (OPG)-A potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 118: 1901-1908.
4. De Toni EN, Thieme SE, Herbst A, Behrens A, Stieber P, Jung A, Blum H, Goke B, Kolligs FT. 2008. OPG is regulated by β-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res 14: 4713-4718.
5. Di Pietro R, Zauli G. 2004. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201: 331-340.
6. Gibellini D, Bassini A, Pierpaoli S, Bertolaso L, Milani D, Capitani S, La Placa M, Zauli G. 1998. Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160: 3891-3898.
7. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. 2010. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28: 2839-2846.
8. Holen I, Croucher PI, Hamdy FC, Eaton CL. 2002. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62: 1619-1623.
9. Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL. 2005. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo-A role in tumour cell survival? Breast Cancer Res Treat 92: 207-215.
10. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960.
11. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, Wang Z, Liu D, Mountz JD, Ohtsuki M, Koopman WJ, Kimberly R, Zhou T. 2003. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 171: 1061-1069.
12. Kobayashi-Sakamoto M, Hirose K, Nishikata M, Isogai E, Chiba I. 2006. Osteoprotegerin protects endothelial cells against apoptotic cell death induced by porphyromonas gengivalis cysteine proteinases. FEMS Microbiol Lett 264: 238-245.
13. Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S. 2008. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 103: 335-345.
14. Lambert C, Oury C, Dejardin E, Chariot A, Piette J, Malaise M, Merville MP, Franchimont N. 2007. Further insights in the mechanisms of interleukin-1beta stimulation of osteoprotegerin in osteoblast-like cells. J Bone Miner Res 22: 1350-1361.
15. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, Holloway D, Bekker P, Dunstan CR. 2002. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8: 2306-2310.
16. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. 2000. Osteoprotegerin is an alpha vbeta3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 275: 20959-20962.
17. Mangan SH, Campenhout AV, Rush C, Golledge J. 2007. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovascular Res 76: 494-505.
18. Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P, Capitani S, Secchiero P. 2003. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86: 126-135.
19. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, Zauli G, Secchiero P, Manzoli FA, Vitale M. 2004. Activated human NK and CD8+ T cells express both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors, but are resistant to TRAIL-mediated cytotoxicity. Blood 104: 2418-2424.
20. Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I. 2004. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86: 269-279.
21. Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC, Eaton CL. 2004. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res 19: 1712-1721.
22. Pantouli E, Boehm MM, Koka S. 2005. Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. Biochem Biophys Res Commun 329: 224-229.
23. Pettersen I, Bakkelund W, Smedsrod B, Sveinbjornsson B. 2005. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res 25: 3809-3816.
24. Pritzker LB, Scatena M, Gianchelli CM. 2004. The role of osteoprotegerin and tumor necrosis factor-related apoptosis inducing ligand in the human microvascular endothelial cell survival. Mol Biol Cell 15: 2834-2841.
25. Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC. 2009. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem 108: 106-116.
26. Secchiero P, Zauli G. 2008. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 15: 42-48.
27. Secchiero P, Sun D, De Vico AL, Crowley RW, Reitz MS, Zauli G, Lusso P, Gallo RC. 1997. Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. J Virol 71: 4571-4580.
28. Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V, Forti G, Capitani S, Zauli G. 2004. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61: 1965-1974.
29. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G. 2005. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105: 3413-3419.
30. Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G. 2006a. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169: 2236-2244.
31. Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, Fabris B, Giacca M, Zauli G. 2006b. Systemic TRAIL delivery shows anti-atherosclerotic activity in apoE-null diabetic mice. Circulation 114: 1522-1530.
32. Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G. 2008. TRAIL promotes migration of human bone marrow multipotent stromal cells. Stem Cells 26: 2955-2963.
33. Shipman CM, Croucher PI. 2003. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63: 912-916.
34. Siegmund D, Klose S, Zhou D, Baumann B, Roder C, Kalthoff H, Wajant H, Trauzold A. 2007. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signaling in pancreatic tumour cells. Cell Signal 19: 1172-1184.
35. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
36. Son JK, Varadarajan S, Bratton SB. 2010. TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. Cell Death Differ 17: 1288-1301.
37. Steele LP, Georgopoulos NT, Southgate J, Selby PJ, Trejdosiewicz LK. 2006. Differential susceptibility to TRAIL of normal versus malignant urothelial cells. Cell Death Differ 13: 1564-1576.
38. Toruner M, Fernandez-Zapico M, Sha JJ, Pham L, Urrutia R, Egan LJ. 2006. Anti-anoikis effect of nuclear factor-kB through upregulated expression of osteoprotegerin, Bcl-2 and IAP-1. J Biol Chem 281: 8686-8696.
39. Vitovski S, Phillips JS, Sayers J, Croucher PI. 2007. Investigating the interaction between osteoprotegerin and RANKL or TRAIL: Evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 282: 31601-31609.
40. Zauli G, Secchiero P. 2006. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 17: 245-257.
41. Zauli G, Corallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, Tedesco F, Secchiero P. 2007. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo Blood 110: 536-543.
42. Zauli G, Melloni E, Capitani S, Secchiero P. 2009. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 66: 841-851.
43. Zhang L, Zhu H, Davis JJ, Jacob D, Wu S, Teraishi F, Gutierrez A, Wang Y, Fang B. 2004. Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biol Ther 3: 296-301.